Vivek Subbiah: Thrilled to announce a groundbreaking – AstraZeneca and Sarah Cannon Docs collaboration

Vivek Subbiah shared a post on X:

“Exciting News in Clinical Trials!

Thrilled to announce a groundbreaking – AstraZeneca and Sarah Cannon Research Institute collaboration – Introducing a game-changing shift from Electronic Health Record (EHR) to Electronic Data Capture (EDC) EHR2EDC (E2E) systems for clinical trial data collection.

Data entry hurdles in clinical trials are real and this partnership aims to revolutionize the process. Our joint efforts will pave the way for streamlined, efficient and more advanced operational processes.

The integration of EHR to EDC signals a crucial evolution in the traditional trial delivery model.
Research sites must adapt to the dynamic drug development landscape. Let’s move towards a future where clinical trials meet the demands of a complex industry.”

View additional information.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.